Cargando…
Approach to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis
For more than a year now, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been causing the coronavirus disease (COVID-19) pandemic with high mortality and detrimental effects on society, economy, and individual lives. Great hopes are being placed on vaccination as one of the most po...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8256163/ https://www.ncbi.nlm.nih.gov/pubmed/34234787 http://dx.doi.org/10.3389/fimmu.2021.701752 |
_version_ | 1783718044810346496 |
---|---|
author | Woopen, Christina Schleußner, Katharina Akgün, Katja Ziemssen, Tjalf |
author_facet | Woopen, Christina Schleußner, Katharina Akgün, Katja Ziemssen, Tjalf |
author_sort | Woopen, Christina |
collection | PubMed |
description | For more than a year now, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been causing the coronavirus disease (COVID-19) pandemic with high mortality and detrimental effects on society, economy, and individual lives. Great hopes are being placed on vaccination as one of the most potent escape strategies from the pandemic and multiple vaccines are already in clinical use. However, there is still a lot of insecurity about the safety and efficacy of vaccines in patients with autoimmune diseases like multiple sclerosis (MS), especially under treatment with immunomodulatory or immunosuppressive drugs. We propose strategic approaches to SARS-CoV-2 vaccination management in MS patients and encourage fellow physicians to measure the immune response in their patients. Notably, both humoral and cellular responses should be considered since the immunological equivalent for protection from SARS-CoV-2 after infection or vaccination still remains undefined and will most likely involve antiviral cellular immunity. It is important to gain insights into the vaccine response of immunocompromised patients in order to be able to deduce sensible strategies for vaccination in the future. |
format | Online Article Text |
id | pubmed-8256163 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-82561632021-07-06 Approach to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Woopen, Christina Schleußner, Katharina Akgün, Katja Ziemssen, Tjalf Front Immunol Immunology For more than a year now, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been causing the coronavirus disease (COVID-19) pandemic with high mortality and detrimental effects on society, economy, and individual lives. Great hopes are being placed on vaccination as one of the most potent escape strategies from the pandemic and multiple vaccines are already in clinical use. However, there is still a lot of insecurity about the safety and efficacy of vaccines in patients with autoimmune diseases like multiple sclerosis (MS), especially under treatment with immunomodulatory or immunosuppressive drugs. We propose strategic approaches to SARS-CoV-2 vaccination management in MS patients and encourage fellow physicians to measure the immune response in their patients. Notably, both humoral and cellular responses should be considered since the immunological equivalent for protection from SARS-CoV-2 after infection or vaccination still remains undefined and will most likely involve antiviral cellular immunity. It is important to gain insights into the vaccine response of immunocompromised patients in order to be able to deduce sensible strategies for vaccination in the future. Frontiers Media S.A. 2021-06-21 /pmc/articles/PMC8256163/ /pubmed/34234787 http://dx.doi.org/10.3389/fimmu.2021.701752 Text en Copyright © 2021 Woopen, Schleußner, Akgün and Ziemssen https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Woopen, Christina Schleußner, Katharina Akgün, Katja Ziemssen, Tjalf Approach to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis |
title | Approach to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis |
title_full | Approach to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis |
title_fullStr | Approach to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis |
title_full_unstemmed | Approach to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis |
title_short | Approach to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis |
title_sort | approach to sars-cov-2 vaccination in patients with multiple sclerosis |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8256163/ https://www.ncbi.nlm.nih.gov/pubmed/34234787 http://dx.doi.org/10.3389/fimmu.2021.701752 |
work_keys_str_mv | AT woopenchristina approachtosarscov2vaccinationinpatientswithmultiplesclerosis AT schleußnerkatharina approachtosarscov2vaccinationinpatientswithmultiplesclerosis AT akgunkatja approachtosarscov2vaccinationinpatientswithmultiplesclerosis AT ziemssentjalf approachtosarscov2vaccinationinpatientswithmultiplesclerosis |